The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Abstract
Background Studies have reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased incidence of cardiovascular disease (CVD). However, the magnitude of the risk and whether this risk changes with the severity of NAFLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CVD events.Methods We systematically searched PubMed, Scopus, and Web of Science from database inception to July 1, 2021, to identify eligible observational studies examining the risk of incident CVD events amongst adult (age ≥18 years) individuals with and without NAFLD and in which NAFLD was diagnosed by imaging, International Classification of Diseases codes, or liver biopsy. The primary outcomes were CVD death, non-fatal CVD events, or both. Data from selected studies were extracted, and meta-analysis was performed using random-effects models to obtain summary hazard ratios (HRs) with 95% CIs. The quality of the evidence was assessed with the Cochrane risk of bias tool. This study is registered on Open Science Framework, number osf.io/5z7gf.Findings We identified 36 longitudinal studies with aggregate data on 5 802 226 middle-aged individuals (mean age 53 years [SD 7]) and 99 668 incident cases of fatal and non-fatal CVD events over a median follow-up of 6·5 years (IQR 5·0-10·2). NAFLD was associated with a moderately increased risk of fatal or non-fatal CVD events (pooled random-effects HR 1·45, 95% CI 1·31-1·61; I 2=86·18%). This risk markedly increased across the severity of NAFLD, especially the stage of fibrosis (pooled random-effects HR 2·50, 95% CI 1·68-3·72; I 2=73·84%). All risks were independent of age, sex, adiposity measures, diabetes, and other common cardiometabolic risk factors. Sensitivity analyses did not modify these results.Interpretation NAFLD is associated with an increased long-term risk of fatal or non-fatal CVD events. CVD risk is further increased with more advanced liver disease, especially with higher fibrosis stage. These results provide evidence that NAFLD might be an independent risk factor for CVD morbidity and mortality.Funding None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall, individuals with MASLD have a higher risk of non-fatal cardiovascular disease (HR 1.40), 25”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although some studies indicated a higher risk of cardiovascular disease-related mortality (HR 1.30), 25,26 others did not con fi rm this result in the general population, but only in those with biopsy-proven MASH 24 or other risk factors like T2D. 15”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhou, Y. J., Li, Y. Y., Nie, Y. Q., Huang, C., & Cao, C. Y. (2011) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2011.00571.x · Cited by 80
RetractedThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,496
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429
Self-citationNonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,251
Cited by
Sorted by citations
Items 201–300 of 691
Zhou, B., Yu, Q., Jiang, X., Mei, Y.-Z., Ding, Y., & Wang, M. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04465-y · Cited by 16
Prognostic value of FIB-4 and NFS for cardiovascular events in patients with and without NAFLD
Zhang, J., Li, L., Lin, L., Wu, Y., Hu, L., Feng, Z., Zhang, D., Fu, T., Zhao, H., Yin, X., et al. (2025) · BMC Public Health · doi:10.1186/s12889-025-23883-x · Cited by 16
The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting
Thrift, A. P., Nguyen, T. H.-A., Pham, C., Balakrishnan, M., Kanwal, F., Loomba, R. S., Duong, H. T., Ramsey, D. J., & El‐Serag, H. B. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.05.046 · Cited by 15
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
Bali, A. D., Rosenzveig, A., Frishman, W. H., & Aronow, W. S. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000537 · Cited by 16
Remnant cholesterol and severity of nonalcoholic fatty liver disease
Huang, H., Wang, J., Wu, L. M., Ruan, J., Hou, L., Shen, C., & Xu, C. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01220-9 · Cited by 15
Shibayama, K., Furushima, C., Saka, M., Sakamoto, T., & Takahashi, H. (2023) · Journal of Rural Medicine · doi:10.2185/jrm.2023-026 · Cited by 15
Hu, Y., Tang, W., Liu, Y., Zhang, N., Zhu, X., Tang, D., Zhang, Y., Xu, H., Duoji, Z., Yang, T., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-01708-5 · Cited by 15
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 15
Chábová, V. Č., & Zakiyanov, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052812 · Cited by 16
Approach to the Patient With Nonalcoholic Fatty Liver Disease
Belfort‐DeAguiar, R., Lomonaco, R., & Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac624 · Cited by 16
Fructose 1-phosphate, an evolutionary signaling molecule of abundancy
Brouwers, M. C. G. J. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.07.007 · Cited by 14
Gaggini, M., Minichilli, F., Gorini, F., Turco, S. D., Landi, P., Pingitore, A., & Vassalle, C. (2022) · Biomedicines · doi:10.3390/biomedicines11010076 · Cited by 14
Cho, Y., Chang, Y., Ryu, S., Kim, C., Wild, S. H., & Byrne, C. D. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002250 · Cited by 15
Self-citationFILIPPO, O. D., Pietro, G. D., Nebiolo, M., Ribaldone, D. G., Gatti, M., Bruno, F., Gallone, G., Armandi, A., Birtolo, L. I., Zullino, V., et al. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14188 · Cited by 14
Theofilis, P., Vordoni, A., & Kalaitzidis, R. (2022) · Metabolites · doi:10.3390/metabo12111070 · Cited by 14
Hua, L., Li, J., Yang, Y., Jiang, D., Jiang, X., Han, X., Jin, C., Feng, B., Che, L., Xu, S., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202202031r · Cited by 14
Martínez‐Domínguez, S. J., García, S. G., Laredo, V., Gargallo-Puyuelo, C. J., Llera, B. G., de la Cruz, J. L., & Gomollón, F. (2023) · Cancers · doi:10.3390/cancers15133367 · Cited by 14
Park, M. K., Hur, M. H., Moon, H., Shin, H., Chung, S. W., Won, S., Lee, Y. B., Cho, E. J., Lee, J., Yu, S. J., et al. (2024) · Liver International · doi:10.1111/liv.15832 · Cited by 14
Desai, R., Alvi, A. T., Vasavada, A. M., Pulakurthi, Y. S., Patel, B. A., Mohammed, A. S., Doshi, S., & Ogbu, I. R. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i3.137 · Cited by 14
AI-Based Models for Risk Prediction in MASLD: A Systematic Review
Njei, B. M., Al‐Ajlouni, Y. A., Lemos, S. Y., Ugwendum, D. F., Njei, N., Ta’ani, O. A., Ameyaw, P. A., Njei, L., & Boateng, S. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09499-6 · Cited by 13
Kueh, M. T. W., Yeo, J. Q., Chen, Y., Chua, N. Y. Z., Koh, H. L., Khaw, S. P., Jabbar, H., Wang, J., Lee, K. S. S., Chin, Y. H., et al. (2026) · Liver International · doi:10.1111/liv.70747 · Cited by 13
Self-citationPrecision medicine in nonalcoholic fatty liver disease
Lonardo, A. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15850 · Cited by 13
McDonough, D. J., Mathew, M., Pope, Z., Schreiner, P. J., Jacobs, D. R., VanWagner, L. B., Carr, J. J., Terry, J. G., Gabriel, K. P., Reis, J. P., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175603 · Cited by 13
Wang, J., Zheng, Z., & Zhang, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15733 · Cited by 13
Wang, J.-J., Zheng, Z., & Zhang, Y. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466469 · Cited by 14
Zhao, J.-F., Zhou, B., Lv, Y., Teng, Q., Wang, X.-M., Li, X., & Ding, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368965 · Cited by 13
Zhong, H., Zhang, K., Lin, L., Yan, Y., Shen, L., Chen, H., Liang, X., Chen, J., Miao, Z., Zheng, J., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02409-6 · Cited by 15
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology
Zhou, X., Targher, G., Byrne, C. D., Shapiro, M. D., Chen, L.-L., & Zheng, M. (2024) · Cardiology Plus · doi:10.1097/cp9.0000000000000106 · Cited by 15
Self-citationOrgan damage proteomic signature identifies patients with MASLD at risk of systemic complications
Pirola, C. J., Diambra, L. A., Gianotti, T. F., Castaño, G. O., Martino, J. S., Garaycoechea, M. E., & Sookoian, S. C. (2025) · Hepatology · doi:10.1097/hep.0000000000001346 · Cited by 13
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Interorgan Crosstalk in Heart Failure and Cardiometabolic Diseases: A Compendium
Schiattarella, G. G., & Kontaridis, M. I. (2025) · Circulation Research · doi:10.1161/circresaha.125.326720 · Cited by 12
SOUZA, M. M. X. D., Al‐Sharif, L., Antunes, V., Wong, S. Y., Huang, D. Q., & Loomba, R. S. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70565 · Cited by 12
Meyhöfer, S. M., Cariou, B., Cercato, C., Colhoun, H. M., Deanfield, J. E., Long, M. T., Jeppesen, O. K., Lincoff, A. M., Lingvay, I., Plutzky, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04281-1 · Cited by 13
Development of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis
Hayashi, M., Kuwabara, Y., Ito, K., Hojo, Y., Arai, F., Kamijima, K., Takeiri, M., Wang, X., Diao, P., Nakayama, J., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020384 · Cited by 12
Association of fatty liver index with sudden cardiac arrest in young adults
Jeong, J. H., Kim, Y. G., Han, K.-D., Roh, S., Lee, H. S., Choi, Y. Y., Yim, S. Y., Shim, J., Kim, Y., & Choi, J. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155981 · Cited by 12
Anastasiou, G., Stefanakis, K., Hill, M. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156044 · Cited by 12
Cernea, S., Onișor, D. M., Roiban, A. L., Benedek, T., & Raț, N. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i10.580 · Cited by 13
BMI gain and dietary characteristics are risk factors of MASLD in non-obese individuals
Taniguchi, H., Ueda, M., Kobayashi, Y., & Shima, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-86424-x · Cited by 12
Xiong, F.-X., Sun, L., Zhang, X.-J., Chen, J., Zhou, Y., Ji, X., Meng, P., Wu, T., Wang, X., & Hou, Y. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i9.101383 · Cited by 12
Lee, Y. H., Lee, J., Jeong, J., Park, K., Baik, B., Kwon, Y., Kim, K., Khim, K. W., Ji, H., Lee, J. Y., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156266 · Cited by 13
Bril, F., Bolla, P., Huynh, K., & Bobba, S. S. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf110 · Cited by 12
Yi, M., Peng, W. J., Teng, F., Kong, Q., & Chen, Z. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002462 · Cited by 12
Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges
Mura, V. L., Bitto, N., & Tripodi, A. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2144217 · Cited by 12
Corbin, K. D., Pittas, A. G., Desouza, C. V., Grdinovac, K., Herzig, K., Kashyap, S. R., Kim, S. H., Nelson, J., Rasouli, N., Vickery, E. M., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108475 · Cited by 12
Schaefer, S. M., Kaiser, A., Eichner, G., & Faßhauer, M. (2024) · Nutrition Journal · doi:10.1186/s12937-024-00926-4 · Cited by 12
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease
Shrestha, A., & Pradhananga, S. (2022) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1359 · Cited by 11
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lange, P. W., Fitzpatrick, J. A., Vaz, K., Lubel, J. S., Hodge, A. D., Ryan, J. L., McNeil, J. J., et al. (2025) · Nutrients · doi:10.3390/nu17132189 · Cited by 12
Impact of cardiac dysfunction on morbidity and mortality in liver transplant candidates
Mohammadi, F., Ramachandran, J., Woodman, R. J., Muller, K., John, L., Chen, J. L., & Wigg, A. J. (2022) · Clinical Transplantation · doi:10.1111/ctr.14682 · Cited by 11
Risk Factors and Prediction Models for Nonalcoholic Fatty Liver Disease Based on Random Forest
Li, Q., Zhang, X., Zhang, C., Li, Y., & Zhang, S. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/8793659 · Cited by 11
Huangfu, G., Jaltotage, B., Pang, J., Lan, N. S. R., Abraham, A., Otto, J. H., Ihdayhid, A. R., Rankin, J. M., Chow, B. J. W., Watts, G. F., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155370 · Cited by 11
Canillas, L., Soriano-Varela, A., Rodríguez-Campello, A., Steinhauer, E. G., Cuadrado‐Godia, E., & Broquetas, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1003878 · Cited by 11
Björnson, E., Samaras, D., Adiels, M., Kullberg, J., Bäckhed, F., Bergström, G. M. L., & Gummesson, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-39390-1 · Cited by 11
Mantovani, A., Morandin, R., Fiorio, V., Lando, M. G., Gaviraghi, A., Motta, L., Gobbi, F. G., Tilg, H., Byrne, C. D., & Targher, G. (2024) · Liver International · doi:10.1111/liv.16101 · Cited by 11
Self-citationPatoulias, D., & Michailidis, T. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00278 · Cited by 10
Heerkens, L., van Kleef, L. A., de Knegt, R. J., Voortman, T., & Geleijnse, J. M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287467 · Cited by 10
Chang, M., Shao, Z., Wei, W., Shen, P.-P., & Shen, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1241169 · Cited by 10
Petralli, G., Salvati, A., Tricò, D., Ricco, G., Colombatto, P., Brunetto, M. R., & Solini, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3736 · Cited by 11
Mantovani, A., Morandin, R., Fiorio, V., Lando, M. G., Petta, S., Ferraro, P. M., & Targher, G. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03705-5 · Cited by 10
Self-citationChoi, Y. J., Park, J.-H., Cho, H.-I., Shin, M., & Nah, E. (2025) · Metabolites · doi:10.3390/metabo15050299 · Cited by 10
Jamalinia, M., Zare, F., & Lonardo, A. (2025) · Health Science Reports · doi:10.1002/hsr2.71530 · Cited by 10
Tachi, K., Agyei-Nkansah, A. A., Atiase, Y., Forkuo, B., & Agyen-Frimpong, V. A. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002294 · Cited by 10
Huang, Y., Huang, J., Chien, H., Lin, C.-I., Chuang, Y., Cheng, H., Lin, W.-T., Lin, Y., Chuang, H., Ho, C.-K., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.08.005 · Cited by 10
Prasad, M., Gupta, S., & Sarin, S. K. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.08.013 · Cited by 11
Waluś‐Miarka, M., Kapusta, M., Miarka, P., Kawalec, E., & Idzior−Waluś, B. (2021) · Cardiovascular Therapeutics · doi:10.1155/2021/7956161 · Cited by 10
Mantovani, A., & Dalbeni, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052882 · Cited by 10
Self-citationIchikawa, K., Lim, J., McClelland, R. L., Susarla, S., Krishnan, S., Benzing, T., Kianoush, S., Aldana-Bitar, J., Manubolu, V. S., & Budoff, M. J. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.123.016465 · Cited by 9
VLDL triglycerides and cholesterol in non-alcoholic fatty liver disease and myocardial infarction
Kyhl, L. K., Nordestgaard, B. G., Tybjærg‐Hansen, A., Smith, G. D., & Nielsen, S. F. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119094 · Cited by 9
Fujiwara, N., Matsushita, Y., Tempaku, M., Tachi, Y., Kimura, G., Izuoka, K., Hayata, Y., Kawamura, S., Eguchi, A., Nakatsuka, T., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001360 · Cited by 10
Attributable burden of steatotic liver disease on cardiovascular outcomes in Asia
Yin, S., Chen, Y.-T., Chang, W., Chen, T.-I., Yang, T.-H., Liu, X.-R., Huang, C.-W., Chen, Y., & Lee, M. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101479 · Cited by 10
Kim, D. W., Son, M., Lee, H. J., Choi, C. H., Kang, Y. W., Moon, S. Y., Koh, M., Lee, J. Y., Baek, Y. H., & An, W. S. (2025) · Hepatology Research · doi:10.1111/hepr.14226 · Cited by 9
Tang, Y., & Gu, C. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1624440 · Cited by 9
Tian, N., Xiao, T., Xia, T., Yuan, H., Shapiro, M. D., Lip, G. Y. H., Fanren, C., Lian, L., Huang, C., Wei, Y., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70306 · Cited by 9
Self-citationMASLD in childhood as a multisystem health challenge beyond the liver
Esposito, M., Rimauro, I., Frattolillo, V., Forcina, G., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.10.001 · Cited by 10
Bian, H., Ma, J., Qu, S., Qian, J., Hao, C., Liu, C., & Gao, X. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-10013-6 · Cited by 9
Malandris, K., Charalampidis, K., Loomba, R. S., & Sinakos, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01621-w · Cited by 9
Кузнецова, А. С., Dolgushina, A., Savochkina, A. Y., Pykhova, L., Sumerkina, V. A., Selyanina, A., Kudrinskaya, Y., & Genkel, V. V. (2022) · Diagnostics · doi:10.3390/diagnostics12102336 · Cited by 9
Henson, J. B., Budoff, M. J., & Muir, A. J. (2022) · Liver International · doi:10.1111/liv.15480 · Cited by 9
Bao, H., Li, J., Zhang, B., Huang, J., Su, D., & Liu, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113634 · Cited by 9
Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease
Armandi, A., Michel, M. S., Gjini, K., Emrich, T., Bugianesi, E., & Schattenberg, J. M. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2242779 · Cited by 9
Gato, S., García‐Fernández, V., Gil‐Gómez, A., Rojas, Á., Montero‐Vallejo, R., Múñoz‐Hernández, R., & Romero‐Gómez, M. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.26 · Cited by 9
Bucci, T., Nabrdalik, K., Baratta, F., Pastori, D., Pignatelli, P., Hydes, T., Alam, U., Violi, F., & Lip, G. Y. H. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae394 · Cited by 9
Common Denominator of MASLD and Some Non-Communicable Diseases
Ferenc, K., Jarmakiewicz-Czaja, S., Sokal-Dembowska, A., Stasik, K., & Filip, R. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070399 · Cited by 9
Sun, M., Qiu, Y., Zhang, L., & Chen, G. (2024) · Scientific Reports · doi:10.1038/s41598-024-74791-w · Cited by 9
Non-Alcoholic Fatty Liver Disease, Awareness of a Diagnostic Challenge—A Clinician’s Perspective
Mărginean, C. M., Pîrșcoveanu, D. F. V., Cazacu, S. M., Popescu, M. S., Mărginean, I. C., Iacob, G. A., & Popescu, M. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15040071 · Cited by 10
The challenge of cardiovascular prevention in NAFLD
Ben, M. D., Baratta, F., Pastori, D., & Angelico, F. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00337-x · Cited by 9
Martínez‐Urbistondo, D., D’Avola, D., Navarro‐González, D., Sánchez‐Íñigo, L., Fernández‐Montero, A., Pérez-Díaz-del-Campo, N., Bugianesi, E., Martínez, J. A., & Delgado, J. P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175190 · Cited by 10
Sulforaphane ameliorates non-alcoholic steatohepatitis by KLF4-mediated macrophage M2 polarization
Huang, X., Xu, J., Xu, Y., Huangfu, B., Zhang, F., Hu, Y., Gao, R., Ren, X., Zhang, B., Huang, K., et al. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250220 · Cited by 8
Deep phenotyping of patients with MASLD upon high-intensity interval training
Houttu, V., Boulund, U., Troelstra, M., Csader, S., Stols‐Gonçalves, D., Mak, A. L., van Dijk, A., Bouts, J., Winkelmeijer, M., Verdoes, X., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101289 · Cited by 8
Cardiovascular Manifestations of Patients with Non-Alcoholic Fatty Liver Disease
Pădureanu, V., Forțofoiu, M.-C., Pîrșcoveanu, M., Pădureanu, R., Rădulescu, D., Donoiu, I., & Pîrșcoveanu, D. F. V. (2025) · Metabolites · doi:10.3390/metabo15030149 · Cited by 8
Pham, H. N., Ibrahim, R., Mouhaffel, R., Abdelnabi, M. H., Öztürk, N. B., Elshaer, A., Habib, E., Farina, J., Ayoub, C., Lee, J. Z., et al. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.06.039 · Cited by 8
Jeong, J., Han, S., Park, G., Park, S.-W., Jeon, Y., Lim, S., Kwon, W. J., Choi, S. H., & Park, N. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-10380-9 · Cited by 8
Chen, X., Du, L., & Peng, J. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04249 · Cited by 8
Hernández-Almonacid, P. G., & Marín-Quintero, X. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i2.111737 · Cited by 8
Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways
Shaheen, A., Baguley, E., Swain, M. G., Tam, M., Ma, M. M., Sebastiani, G., Jiang, J., Lee, F. S.-H., Medellin, A., & Abraldeṣ, J. G. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101735 · Cited by 8
Mantovani, A., Scoccia, E., Morandin, R., Lando, M. G., Fiorio, V., Taverna, A., Milani, I., Chinucci, M., Parrotta, M. E., Colangeli, L., et al. (2026) · Liver International · doi:10.1111/liv.70514 · Cited by 8
Self-citationAkuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., 疋田隼人, et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02408-2 · Cited by 9
Lee, J., Jo, G., Park, D., Jun, H. J., Bae, J. H., & Shin, M. (2023) · Nutrients · doi:10.3390/nu15061501 · Cited by 8
Zhao, Y., He, Y., Zhang, L., Liu, J., Bai, Y., Wang, M., & Zheng, S. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.09.009 · Cited by 8
Influence of MAFLD and NAFLD on arterial stiffness: A longitudinal cohort study
Yoo, T. K., Lee, S. W., Lee, M. Y., Choi, H., & Sung, K. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.03.008 · Cited by 8
Metadata
- Authors
- Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G.
- Affiliations
- University of Verona (IT)
- Harvard University (US)
- Southampton General Hospital (GB)
- Corresponding author
- Targher, Giovanni
- ORCID
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 6
- Issue
- 11
- Pages
- 903-913
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W3201276384
- Cited by
- 674
- References
- 75
- Citations by year
- 2026: 160 · 2025: 151 · 2024: 141 · 2023: 122 · 2022: 95 · 2021: 4
- FWCI
- 13.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- The Lancet. Gastroenterology & hepatology (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Funders
- National Institute for Health Research Southampton Biomedical Research Centre (IS-BRC-20004)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular mortality, cardiovascular events, liver fibrosis, disease severity, cardiometabolic risk factors, cardiovascular risk factors, middle-aged adults, NAFLD staging
- MeSH terms
- Cardiovascular Diseases, Humans, Risk Factors, Severity of Illness Index, Models, Statistical, Survival Analysis, Observational Studies as Topic, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
